Bioiberica whises to inform its customers that its heparin sodium is fully compliant with the new requirements established by the Heparin Sodium USP monograph revision that is effective in USP 37 NF32, on May 1st, 2014.
Bioiberica just opened a new production site of Heparin derivatives within the expansion plan of its Science portfolio.
As every year Bioiberica will attend the CPHI Fair.
Bioiberica participated in two studies to establish the standard ranges of activity of Anti-factor Xa and anti-IIa of sodium heparin organized by EDQM, which will be included in the new revision of the monograph of the European Pharmacopoeia.
Last May Bioiberica had a non scheduled inspection from the US FDA in its facility in Geneva (Nebraska) where the first steps of heparin sodium production are performed.